Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Inv. presentation
Appointed CFO
Quarterly results
CC transcript
VALEANT PHARMACEUTICALS INTERNATIONAL (VRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/13/2008 8-K Investor presentation
Docs: "Presentation by the Company of the results of the second of two studies (RESTORE 2) in its Phase III clinical trials for retigabine",
"VALEANT ANNOUNCES SUCCESFUL COMPLETION OF RETIGABINE PHASE III EPILEPSY PROGRAM VALIDATING NOVEL MECHANISM OF ACTION"
03/27/2008 8-K Investor presentation
Docs: "Presentation by the Company"
02/14/2008 8-K Investor presentation
Docs: "Presentation by the Company of the results of the first of two studies (RESTORE 1) in its Phase III clinical trials for retigabine",
"VALEANT PHARMACEUTICALS REPORTS POSITIVE PHASE III RESULTS FOR RETIGABINE IN RESTORE 1"
09/10/2007 8-K Investor presentation
Docs: "Presentation by the Company at the Bear Stearns 20th Annual Health Care Conference",
"Reconciliation of non-GAAP measures to the most directly comparable measure calculated in accordance with GAAP"
09/12/2006 8-K Investor presentation
Docs: "Presentation by the Company at the Bear Stearns 19th Annual Health Care Conference",
"Reconciliation of non-GAAP measures to the most directly comparable measure calculated in accordance with GAAP",
"VALEANT PHARMACEUTICALS RECEIVES INFORMAL INQUIRIES FROM SEC",
"— Company Initiates Phase 2b Weight-Based Dose-Ranging Study —"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy